The Experts below are selected from a list of 126 Experts worldwide ranked by ideXlab platform
Adil J. Nazarali - One of the best experts on this subject based on the ideXlab platform.
-
A novel method of eliminating non-neuronal proliferating cells from cultures of mouse dorsal root ganglia.
Cellular and Molecular Neurobiology, 2003Co-Authors: Parker L. Andersen, J. Ronald Doucette, Adil J. NazaraliAbstract:1. We hypothesized that non-neuronal cells could be eliminated from primary dorsal root ganglion (DRG) cultures by including a DNA Topoisomerase Inhibitor (camptothecin) during culture.
-
A Novel Method of Eliminating Non-Neuronal Proliferating Cells from Cultures of Mouse Dorsal Root Ganglia
Cellular and Molecular Neurobiology, 2003Co-Authors: Parker L. Andersen, J. Ronald Doucette, Adil J. NazaraliAbstract:1. We hypothesized that non-neuronal cells could be eliminated from primary dorsal root ganglion (DRG) cultures by including a DNA Topoisomerase Inhibitor (camptothecin) during culture. 2. Exposure to 20 μM camptothecin for 48 h, beginning at 3 days in vitro, reliably eliminates proliferating non-neuronal cells. 3. Following camptothecin treatment, neurons survived and continued to extend neurites for several weeks without obvious defects in morphology or viability. 4. Transient camptothecin exposure is therefore an efficient and fast-acting method to purify DRG neurons in culture.
Parker L. Andersen - One of the best experts on this subject based on the ideXlab platform.
-
A novel method of eliminating non-neuronal proliferating cells from cultures of mouse dorsal root ganglia.
Cellular and Molecular Neurobiology, 2003Co-Authors: Parker L. Andersen, J. Ronald Doucette, Adil J. NazaraliAbstract:1. We hypothesized that non-neuronal cells could be eliminated from primary dorsal root ganglion (DRG) cultures by including a DNA Topoisomerase Inhibitor (camptothecin) during culture.
-
A Novel Method of Eliminating Non-Neuronal Proliferating Cells from Cultures of Mouse Dorsal Root Ganglia
Cellular and Molecular Neurobiology, 2003Co-Authors: Parker L. Andersen, J. Ronald Doucette, Adil J. NazaraliAbstract:1. We hypothesized that non-neuronal cells could be eliminated from primary dorsal root ganglion (DRG) cultures by including a DNA Topoisomerase Inhibitor (camptothecin) during culture. 2. Exposure to 20 μM camptothecin for 48 h, beginning at 3 days in vitro, reliably eliminates proliferating non-neuronal cells. 3. Following camptothecin treatment, neurons survived and continued to extend neurites for several weeks without obvious defects in morphology or viability. 4. Transient camptothecin exposure is therefore an efficient and fast-acting method to purify DRG neurons in culture.
J. Ronald Doucette - One of the best experts on this subject based on the ideXlab platform.
-
A novel method of eliminating non-neuronal proliferating cells from cultures of mouse dorsal root ganglia.
Cellular and Molecular Neurobiology, 2003Co-Authors: Parker L. Andersen, J. Ronald Doucette, Adil J. NazaraliAbstract:1. We hypothesized that non-neuronal cells could be eliminated from primary dorsal root ganglion (DRG) cultures by including a DNA Topoisomerase Inhibitor (camptothecin) during culture.
-
A Novel Method of Eliminating Non-Neuronal Proliferating Cells from Cultures of Mouse Dorsal Root Ganglia
Cellular and Molecular Neurobiology, 2003Co-Authors: Parker L. Andersen, J. Ronald Doucette, Adil J. NazaraliAbstract:1. We hypothesized that non-neuronal cells could be eliminated from primary dorsal root ganglion (DRG) cultures by including a DNA Topoisomerase Inhibitor (camptothecin) during culture. 2. Exposure to 20 μM camptothecin for 48 h, beginning at 3 days in vitro, reliably eliminates proliferating non-neuronal cells. 3. Following camptothecin treatment, neurons survived and continued to extend neurites for several weeks without obvious defects in morphology or viability. 4. Transient camptothecin exposure is therefore an efficient and fast-acting method to purify DRG neurons in culture.
Alan Sandler - One of the best experts on this subject based on the ideXlab platform.
-
Irinotecan plus cisplatin in small-cell lung cancer.
Oncology (Williston Park N.Y.), 2020Co-Authors: Alan SandlerAbstract:The DNA Topoisomerase Inhibitor irinotecan (CPT-11, Camptosar) is being evaluated as a novel chemotherapeutic agent for small-cell lung cancer that may complement other agents and treatment modalities. Combination chemotherapy is recognized as the most effective means of improving survival in patients with extensive-stage small-cell lung cancer, but until recently, no one combination had emerged as superior. In a recent Japanese phase III study, irinotecan in combination with cisplatin significantly improved survival of previously untreated patients with extensive small-cell lung cancer compared with standard etoposide/cisplatin therapy (median progression-free survival: 6.9 vs 4.8 months, P < .001; median overall survival: 12.8 vs 9.4 months, P = .0021). Two additional phase III trials are planned to confirm these results in the United States, and to investigate how the irinotecan/cisplatin administration schedule may be modified to improve therapeutic index. This article will review the use of irinotecan in combination with cisplatin in patients with small-cell lung cancer.
-
Irinotecan Plus Cisplatin in Small-Cell Lung Cancer
Oncology, 2002Co-Authors: Alan SandlerAbstract:The DNA Topoisomerase Inhibitor irinotecan (CPT-11, Camptosar) is being evaluated as a novel chemotherapeutic agent for small-cell lung cancer that may complement other agents and treatment modalities. Combination
Kengo Sakaguchi - One of the best experts on this subject based on the ideXlab platform.
-
a novel DNA Topoisomerase Inhibitor dehydroebriconic acid one of the lanostane type triterpene acids from poria cocos
Cancer Science, 2004Co-Authors: Yoshiyuki Mizushina, Toshihiro Akihisa, Motohiko Ukiya, Chikako Murakami, Isoko Kuriyama, Xianai Xu, Hiromi Yoshida, Kengo SakaguchiAbstract:Traditional Chinese medicinal plants are a treasure house for screening novel Inhibitors of DNA polymerases and DNA Topoisomerases from mammals; in the present study, nine lanostanetype triterpene acids were found in sclerotium of Poria cocos. Among the nine compounds, only dehydroebriconic acid could potently inhibit DNA Topoisomerase II (topo II) activity (IC50=4.6 μM), while the compound moderately inhibited the activities of DNA polymerases α, β, γ, δ, ɛ, η, iota;, κ and λ only from mammals, to similar extents. Another compound, dehydrotrametenonic acid, also showed moderate Inhibitory effects against topo II (IC50=37.5 μM) and weak effects against all the polymerases tested. Both compounds showed no Inhibitory effect against topo I, higher plant (cauliflower) DNA polymerase I (α-like polymerase) or II (βlike polymerase), calf thymus terminal deoxynucleotidyl transferase, human immunodeficiency virus type-1 reverse transcriptase, prokaryotic DNA polymerases such as the Klenow fragment of E. coli DNA polymerase I, Taq DNA polymerase and T4 DNA polymerase, or DNA metabolic enzymes such as T7 RNA polymerase, T4 polynucleotide kinase and bovine deoxyribonu-clease I. These findings suggest that dehydroebriconic acid and dehydrotrametenonic acid should be designated as topo II-preferential Inhibitors, although they also moderately inhibited all the mammalian DNA polymerases tested. Both dehydrotrametenonic acid and dehydroebriconic acid could prevent the growth of human gastric cancer cells, and their LD50 values were 63.6 and 38.4 μM, respectively. The cells were halted at the G1 phase in the cell cycle. The relation between the structure of triterpene acids and their Inhibitory activities is discussed.